Results 181 to 190 of about 112,766 (266)
Apolipoprotein B - An ideal biomarker for atherosclerosis? [PDF]
Singh K, Prabhakaran D.
europepmc +1 more source
In a nationally representative Finnish cohort, screen‐detected coeliac disease was associated with iron deficiency, anaemia, and an atherogenic lipid profile at diagnosis, but long‐term gluten‐free treatment did not adversely affect quality of life, metabolic health, or mortality; supporting a favourable benefit‐harm balance for population‐based ...
Iida Ahonen +5 more
wiley +1 more source
Measure Apolipoprotein B If We Believe What We Say About Precision Medicine. [PDF]
Wolska A, Lloyd-Jones DM, Remaley AT.
europepmc +1 more source
We generated digital pathologic algorithms (AI‐based modules that can be freely shared) to: optimize the sampling (ROI) for diagnosis of ADNC‐related tau pathology; compare/transition between Aperio and HALO platforms; and rationalize severe Braak NFT staging, so that all Braak‐VI cases had dementia, and all Braak‐V cases had MCI or dementia.
Ryan K. Shahidehpour +10 more
wiley +1 more source
Low apolipoprotein B and LDL-cholesterol are associated with the risk of cardiovascular and all-cause mortality: a prospective cohort. [PDF]
Yu X +7 more
europepmc +1 more source
This study investigates amyloid‐beta (Aβ) pathology in a forensic autopsy cohort of relatively young individuals (40–69 years). Using detailed immunohistochemical analyses of multiple Aβ species, we demonstrate marked regional and molecular heterogeneity, particularly within the striatum.
Shojiro Ichimata +4 more
wiley +1 more source
Moving Beyond LDL-C and Non-HDL-C: Apolipoprotein B as the Stronger Lipid-Related Predictor of Coronary Artery Disease in Statin-Treated Patients. [PDF]
Jigoranu RA +14 more
europepmc +1 more source
Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes
Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley +1 more source
Association between total and regional body fat measured by dual-energy X-ray absorptiometry and apolipoprotein B. [PDF]
Chen C +11 more
europepmc +1 more source
The current obesity drug landscape, dominated by GLP‐1 receptor agonists and emerging multi‐agonist therapies, has reinforced that long‐term weight loss is achieved in large part through central mechanisms that suppress appetite and reshape energy balance.
Ines Martinez‐Corral +3 more
wiley +1 more source

